RyVent™ is contraindicated in children younger than 2 years of age, in nursing mothers and in patients who are hypersensitive to the drug or on monoamine oxidase inhibitor.

Deaths have been reported in children less than 2 years of age who were taking antihistamines, including carbinoxamine-containing drug products. Antihistamines should be used with considerable caution in patients with: narrow angle glaucoma, stenosing peptic ulcer, symptomatic prostatic hypertrophy, bladder neck obstruction, pyloroduodenal obstruction.

As many other antihistamines, carbinoxamine maleate has an atropine-like action and, therefore, should be used with caution in patients with: increased intraocular pressure, hyperthyroidism, cardiovascular disease, hypertension. Antihistamines such as carbinoxamine maleate should not be used to treat lower respiratory tract symptoms, including asthma.

The most frequent side effects of RyVent™ are sedation, sleepiness, dizziness, disturbed coordination, epigastric distress and thickening of bronchial secretions.

Monoamine oxidase inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines. Carbinoxamine maleate has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc.).

Health care providers and patients are encouraged to report adverse events in patients taking RyVent™ to Carwin Pharmaceutical Associates at 1-844-700-5011. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

See full product information for complete prescribing information before prescribing RyVent™.